Senator John Fetterman, a democrat from Pennsylvania, admitted to using weight loss drug Mounjaro and issued a desperate plea ...

Trump doubled down on plans to soon impose “major” pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.

To that end, let's consider five excellent growth-oriented companies to invest in on the dip: Novo Nordisk ( NVO -1.69%), Eli ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

Mounjaro, a new treatment for Type 2 diabetes and obesity, has been launched in India after CDSCO approval. The drug, ...

Across Wall Street, 44 publicly traded companies were upgraded Tuesday to an equivalent rating of "buy" or "neutral." ...

GLP-1 receptor agonists and SGLT2 inhibitors are associated with a lower risk of dementia, suggesting these drugs may have a ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better ...

The Trump administration rejected a proposed rule to allow Medicare to cover blockbuster obesity drugs for weight loss alone ...

The CMS has opted not to move forward with a plan that would have extended Medicare coverage to obesity drugs for millions of ...